Research ExplorerPublicationsCost-effectiveness of 12-month therapeutic assertive communi...

Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).

Standard

Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). / Karow, Anne; Reimer, Jens; König, Hans-Helmut; Heider, Dirk; Bock, Thomas; Huber, Christian; Schöttle, Daniel; Meister, Klara; Rietschel, Liz; Ohm, Gunda; Schulz, Holger; Naber, Dieter; Schimmelmann, Benno Graf; Lambert, Martin.

In: J CLIN PSYCHIAT, Vol. 73, No. 3, 3, 2012, p. 402-408.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karow, A, Reimer, J, König, H-H, Heider, D, Bock, T, Huber, C, Schöttle, D, Meister, K, Rietschel, L, Ohm, G, Schulz, H, Naber, D, Schimmelmann, BG & Lambert, M 2012, 'Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).', J CLIN PSYCHIAT, vol. 73, no. 3, 3, pp. 402-408. <http://www.ncbi.nlm.nih.gov/pubmed/22490266?dopt=Citation>

APA

Karow, A., Reimer, J., König, H-H., Heider, D., Bock, T., Huber, C., Schöttle, D., Meister, K., Rietschel, L., Ohm, G., Schulz, H., Naber, D., Schimmelmann, B. G., & Lambert, M. (2012). Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J CLIN PSYCHIAT, 73(3), 402-408. [3]. http://www.ncbi.nlm.nih.gov/pubmed/22490266?dopt=Citation

Vancouver

Karow A, Reimer J, König H-H, Heider D, Bock T, Huber C et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J CLIN PSYCHIAT. 2012;73(3):402-408. 3.

Bibtex

@article{cc28c7692b89453abe976455470be809,
title = "Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).",
abstract = "To compare the 1-year cost-effectiveness of therapeutic assertive community treatment (ACT) with standard care in schizophrenia. ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system.",
author = "Anne Karow and Jens Reimer and Hans-Helmut K{\"o}nig and Dirk Heider and Thomas Bock and Christian Huber and Daniel Sch{\"o}ttle and Klara Meister and Liz Rietschel and Gunda Ohm and Holger Schulz and Dieter Naber and Schimmelmann, {Benno Graf} and Martin Lambert",
year = "2012",
language = "English",
volume = "73",
pages = "402--408",
journal = "J CLIN PSYCHIAT",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).

AU - Karow, Anne

AU - Reimer, Jens

AU - König, Hans-Helmut

AU - Heider, Dirk

AU - Bock, Thomas

AU - Huber, Christian

AU - Schöttle, Daniel

AU - Meister, Klara

AU - Rietschel, Liz

AU - Ohm, Gunda

AU - Schulz, Holger

AU - Naber, Dieter

AU - Schimmelmann, Benno Graf

AU - Lambert, Martin

PY - 2012

Y1 - 2012

N2 - To compare the 1-year cost-effectiveness of therapeutic assertive community treatment (ACT) with standard care in schizophrenia. ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system.

AB - To compare the 1-year cost-effectiveness of therapeutic assertive community treatment (ACT) with standard care in schizophrenia. ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system.

M3 - SCORING: Journal article

VL - 73

SP - 402

EP - 408

JO - J CLIN PSYCHIAT

JF - J CLIN PSYCHIAT

SN - 0160-6689

IS - 3

M1 - 3

ER -